Local Institution

Créteil 9410

0 studies enrolling now · 37 studies all time

What they study most

Acute Ischemic Stroke, Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma, Chronic Hepatitis B, Chronic Hepatitis C, Chronic Kidney Failure, Chronic Phase Chronic Myeloid Leukemia, Deep-Vein Thrombosis, Heart Failure, Hepatitis C, Hepatitis C Infection, Hepatitis C Virus, Hepatitis C Virus (HCV)

Studies at this site

• A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel — Completed
• Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC — Completed
• Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens — Completed
• Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) — Completed
• Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) — Completed
• Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure — Completed
• A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based — Completed
• Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial — Completed
• Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment — Completed
• Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed
• Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant — Completed
• Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications — Completed
• Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma — Completed
• Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus — Completed
• Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib — Completed
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed
• First Line Hepato Cellular Carcinoma (HCC) — Completed
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML — Completed
• Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) — Completed
• Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials — Completed
• Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection — Completed
• Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients — Completed
• Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) — Completed
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
• Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C — Completed
• Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials) — Completed
• Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin — Completed
• Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin — Completed
• Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care — Completed
• Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed
• UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis — Completed
• Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial — Completed
• Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis — Stopped early
• Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML — Completed
• Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study — Completed